Tandem Labs
当社が顧客の期待以上の成果を出せるのは、当社スタッフの専門知識と優れた対応能力のたまものです。経営陣が第一に考えるのは、最適のスタッフを集め、高い達成感と仕事への満足感が得られる職場環境と資源を彼らに提供することです。スタッフ個々の職務達成感を重視することで、社内が安定し、またそれが顧客ニーズをしっかり把握することにつながります。
James K. Wilfahrt, BSMT (ASCP), M.B.A.
Vice President, Operations
General Manager, Bioanalytical Services
James K. Wilfahrt has overall responsibility for the Utah, New Jersey, and Massachusetts bioanalytical operations. Mr. Wilfahrt joined Tandem Labs in 1991 as quality control manager. Mr. Wilfahrt held the positions of business development manager and operations manager prior to his current position. Before Tandem, Mr. Wilfahrt was the laboratory director for the division of infectious disease at Intermountain Healthcare in Salt Lake City, Utah.
Edward Brewer, M.S.
Senior Laboratory Director, Biotechnology Division, New Jersey Facility
Edward Brewer leads laboratory operations for the biotechnology division at the New Jersey facility. He joined Tandem Labs in 1999 and has been involved in bioanalytical mass spectrometry since 1987. His expertise comes from experience within large pharma and contract research organizations. Mr. Brewer was formerly the section head of drug discovery at Advanced BioAnalytical Services, Inc.
Spencer Carter, Ph.D.
Associate Laboratory Director, Utah Facility
Spencer Carter joined Tandem Labs in 2001. He graduated from the University of Alberta with a degree in Analytical Chemistry. His research focused on the analysis of tamoxifen metabolites by nonaqueous CE/MS. Dr. Carter leads a group and oversees the analysis of clinical studies at the Salt Lake City facility. He also oversees the development of non-proprietary assays for Tandem Labs.
Laura Cojocaru
Senior Laboratory Director, Bioanalytical Division, New Jersey Facility
Prior to Tandem Labs, Ms. Cojocaru served as the director of the bioanalytical department for Huntingdon Life Sciences. Previously, she was a senior manager in the bioanalytical department at Phoenix International Life Sciences in Montreal, Canada and a laboratory supervisor at Anachemia Canada, Inc., among others. Ms. Cojocaru brings more than 25-years of laboratory management experience to Tandem Labs. Ms. Cojocaru also possesses several inventor certificates for a number of procedures including one for obtaining L-Cysteine HCL and one for the extraction and purification of a hyaluronidase inhibitor of animal origin.
Roger Demers, B.Sc.
Group Leader, New Jersey Facility
Roger Demers is based in West Trenton, NJ. Mr. Demers has 17 years of experience with various mass spectrometry platforms, including 15 years with triple quadrupoles. He was one of the first in the world to use an API-III+ in 1989 (S/N 008) to quantitate NCEs in biological matrices commercially. Previously, Mr. Demers was the senior mass spectrometry scientist at Maxxam Analytics, Canada. In the past several years, Mr. Demers has developed and validated hundreds of bioanalytical methods on LC/MS/MS. His practical experience and expertise makes him one of the best method development scientists in the industry. He joined Tandem Labs, New Jersey in October 2004.
Xiguang (Lisa) Li , M.D.
Research Scientist, Biotechnology Division
Dr. Li adds nearly 35-years of senior research experience to Tandem Labs’ Biotechnolgoy Division. Prior to Tandem Labs, Dr. Li was a research associate for Enzon Pharmaceuticals, Immunomedics, Johnson & Johnson, and Merck and Co., among others. Dr. Li brings with her a remarkable background in the development, validation, and sample analysis of assays using ELISA and other advanced technologies. She also has extensive experience in conducting flow cytometry experiments on cell lines as well as in immunogenicity and pharmacokinetics. Dr. Li earned her M.D. in Clinical Medicine from the Third Military Medical University of China in Chong Qing, P.R. China.
Min Meng, Ph.D.
Associate Laboratory Director, Utah Facility
Dr. Min Meng joined Tandem Labs in 1998 and is based in Salt Lake City, Utah. Dr. Meng is currently leading all method development, validation projects, and pre-clinic sample analysis at the Salt Lake City facility. Dr. Meng has nearly 15 years of experience in the bioanalytical field and is recognized as a technical expert in method development, validation, and sample analysis using LC/MS/MS in supporting regulated bioanalysis. Dr. Meng earned her Ph.D. in Biomedicinal Chemistry from University of Maryland and B.S. and M.S. degrees from Beijing Normal University, P.R. China.
Scott A. Reuschel, M.S.F.S.
Laboratory Director, Utah Facility
Scott Reuschel joined Tandem Labs in November 1993 and is based in Salt Lake City, Utah. In his role as Laboratory Director, Mr. Reuschel oversees the efficient, reliable operation of the laboratory; directs operational improvements and evaluations of new technologies, software platforms, and laboratory information management systems; and actively participates in strategic planning and process improvements. Mr. Reuschel has nearly 20 years of experience in the bioanalytical field and is recognized as a technical expert in method development and validation. Prior to Tandem Labs, Mr. Reuschel worked at AccuTox Analytical Laboratories in Attalla, Alabama.
KC Van Horne, B.Sc.
Director, Process Innovation and Automation
KC Van Horne has over 30 years experience in sample preparation and separation sciences. Mr. Van Horne developed Tandem’s approach to rapid bioanalytical method development, standardized Tandem’s analytical platforms to achieve company-wide utility/flexibility for various analytical methods, and implemented Symbiosis, a fully-automated platform for on-line solid phase extraction of samples prior to bioanalysis. He was a primary contributor in discovering matrix effects due to endogenous phospholipids in biological samples, a now widely-acknowledged component of method ruggedness for bioanalytical LC-MS/MS methods. Ongoing projects include full automation of Tandem’s Biotechnology Division, implementing rapid, in-silico method development using intelligent databases and predictive chemistry, and investigation of dried blood spot (DBS) technology for sample collection, storage, and subsequent bioanalysis.
Michael VanTyne
Director, Information Systems
Michael VanTyne began working with Tandem Labs’ parent company in 1994 and currently oversees the Information Systems effort at Tandem Labs. Mr. VanTyne is an accomplished information systems professional with an outstanding track record in strategic planning, regulatory compliance for computerized systems, and technical direction. His achievements at Tandem Labs have included implementation of several comprehensive technologies and applications such Citrix Metaframe, the VelQuest SmartLab electronic lab notebook, Thermo Watson LIMS, and Waters NuGenesis SDMS. Mr. VanTyne has an Oracle Master Certification and has been a featured speaker on various subjects, including “System Ergonomics in a GLP Laboratory” at the International Meeting on Automated Compliance in May 2005.
Laixin Wang, Ph.D.
Method Development Group Leader, Utah Facility
Dr. Wang directs method development, method validation and sample analysis of pre-clinical dose formulations, discovery bioanalytical projects, and GLP bioanalysis of large-molecule drugs. His expertise includes the synthesis, formulation, and bioanalysis of oligonucleotide and peptide therapeutics. After receiving a Ph.D. in medicinal chemistry at Beijing Medical University in 1992 with a thesis on the synthesis of modified oligonucleotides as anticancer agents, Dr. Wang focused on the delivery/formulation of antisense and ribozyme oligonucleotide drugs at the University of Utah, and developed a new method for the synthesis of oligonucleotide arrays (DNA chips) at Duke University. From 2000 until joining Tandem Labs in 2004, he managed the synthesis, formulation, and evaluation of new delivery vehicles for oligonucleotide and hydrophobic drugs at Genta, Inc. (previously Salus Therapeutics).
Search